22.7 C
New York
Monday, June 8, 2026

Tag: genetics

New APOE4 App Uses AI Digital Twins to Help 25% of Population at High Alzheimer’s Risk

Phoenix platform matches users with genetically similar people to predict which interventions actually work.

Draig Therapeutics Appoints Experienced Biotech Leader Douglas E. Williams, Ph.D. as Chair of its Board of Directors

Cardiff, United Kingdom – 15 July 2025 – Draig Therapeutics (“Draig”), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, today announces the appointment of Douglas E. Williams, Ph.D. as independent Chair of its Board of Directors. He takes over from Ruth McKernan, who retains her role on the Board as a Director and Interim Chief Executive Officer (CEO).

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity –

Disposable Weed Pen: Premium Award-Winning All-in-One THC Vaporizers Launched by Area 52

Area 52 launches its new line of Disposable Weed Pens – backed by a 90-day 100% money back satisfaction guarantee.
Area 52 launches its new line of Disposable Weed Pens – backed by a 90-day 100% money back satisfaction guarantee.

Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

Complete Response Letter (CRL) cited specific chemistry, manufacturing and controls (CMC) related observations that are resolvable

Exhale Wellness Ranked No.1 THCA Flower Brand in 2025

Exhale Wellnes was recently ranked No.1 THCA flower brand by industry peers. Read more about its product line, bestsellers, and why it stood out.
Exhale Wellnes was recently ranked No.1 THCA flower brand by industry peers. Read more about its product line, bestsellers, and why it stood out. 

TEM INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action...

SAN DIEGO, July 10, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock...

Rubicon Organics to Hold Annual General and Special Meeting

VANCOUVER, British Columbia, July 10, 2025 (GLOBE NEWSWIRE) -- Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics” or the “Company”), a licensed producer focused on cultivating and selling organic certified and premium cannabis, is pleased to announce that it will hold its Annual General and Special Meeting (the “Meeting”) of shareholders at 10:00 AM PT on July 31, 2025 in person at the Terminal City Club, 837 West Hastings Street, Vancouver, British Columbia, V6C 1B6, for the following purposes:

Maze Therapeutics to Participate in Two Upcoming Investor Conferences

Maze Therapeutics to Participate in Two Upcoming Investor Conferences

Yale School of Medicine Receives $27.7 Million Grant Toward Autism Research

NEW HAVEN, Conn., July 8, 2025 /PRNewswire-HISPANIC PR WIRE/ -- Yale School of Medicine (YSM) was awarded a $27.7 million grant from Aligning Research...

Yale School of Medicine Receives $27.7 Million Grant Toward Autism Research

NEW HAVEN, Conn., July 8, 2025 /PRNewswire/ -- Yale School of Medicine (YSM) was awarded a $27.7 million grant from Aligning Research to Impact...

Belay Diagnostics Announces the Validation of Vantage™ Assay for Evaluation of MGMT Promoter Methylation in Cerebrospinal Fluid

Validation Data on 60 Patients published in Cancer Genetics CHICAGO, July 7, 2025 /PRNewswire/ -- Belay Diagnostics, a CLIA/CAP accredited laboratory focused on the development...

mRNA Sequencing Market Size to Hit USD 4.02 billion by 2031, Growing at 13.6% CAGR, Benefits from Surging Prevalence of Cancer | The Insight...

NEW YORK, July 7, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global mRNA sequencing market is observing...

National Heart, Lung, and Blood Institute / National Institutes of Health Signs Clinical Trial Agreement with Vascarta Inc. to Perform Phase 1 Clinical Study...

SUMMIT, N.J., July 7, 2025 /PRNewswire/ -- Under the agreement, the National Heart, Lung, and Blood Institute / National Institutes of Health will perform...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsGenetics